Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Limited, low-certainty evidence for pharmacological treatments used alone or adjunctively in painful intra-articular temporomandibular disorders: a systematic review and network meta-analysis.

Odontology·2026
Same author

Deep Learning Models for Detection of Periapical Radiolucent Lesions on Panoramic Radiographs: A Systematic Review and Meta-Analysis.

International endodontic journal·2026
Same author

Piecing together the alveolar-capillary unit: arterial-venous capillary polarization.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Engineering function in lung biology: integrating imaging, regenerative constructs, and functional biodesign.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Authors' Reply to 'Methodological Considerations for Surveys of Dental Students' Knowledge and Attitudes Towards Artificial Intelligence in Oral Cancer Diagnosis'.

Oral diseases·2026
Same author

Correction: Infoveillance of COVID-19 Infections in Dentistry Using Platform X: Descriptive Study.

Journal of medical Internet research·2026

Related Experiment Video

Updated: Jun 13, 2026

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

Sustained steroid release in pulmonary inflammation model.

Harry Karmouty-Quintana1, Faleh Tamimi, Toby K McGovern

  • 1Meakins-Christie Laboratories, McGill University, Montreal, Quebec, Canada.

Biomaterials
|May 18, 2010
PubMed
Summary

Calcium pyrophosphate microspheres offer controlled drug release for lung conditions. These novel particles demonstrated sustained anti-inflammatory effects in vivo without causing toxicity, indicating potential for inhaled therapies.

Related Experiment Videos

Last Updated: Jun 13, 2026

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Pharmacology

Background:

  • Inhaled drug delivery requires particles with controlled release for targeted lung therapies, including anti-cancer, bronchodilators, and antiviral agents.
  • Calcium pyrophosphate (CPP) nanofibrous microspheres are a novel material with potential for controlled release applications.

Purpose of the Study:

  • To evaluate the acute toxicity, biodistribution, and controlled release capacity of CPP microspheres loaded with dexamethasone phosphate (Dex-P) in an in vivo model of airway inflammation.
  • To assess the anti-inflammatory efficacy of Dex-P loaded CPP microspheres.

Main Methods:

  • CPP microspheres were loaded with dexamethasone phosphate (Dex-P).
  • In vitro drug release profiles were characterized.
  • Unloaded and Dex-P loaded CPP microspheres were administered intra-tracheally to rats.
  • Tissue reaction to unloaded microspheres was assessed.
  • Anti-inflammatory properties were evaluated using an in vivo model of airway inflammation induced by compound 48/80.

Main Results:

  • Unloaded CPP microspheres showed no inflammatory response at doses below 3mg and were cleared via mucus mechanisms.
  • Dex-P loaded CPP microspheres inhibited eosinophil and total inflammatory cell increases in bronchoalveolar lavage fluid for 42 hours after a single dose.
  • These effects were observed with the microspheres, not with Dex-P alone.

Conclusions:

  • Calcium pyrophosphate nanofibrous microspheres exhibit in vivo controlled release properties.
  • The microspheres are well-tolerated in the lung and do not accumulate.
  • These findings support the potential of CPP microspheres as a delivery system for inhaled anti-inflammatory therapies.